Intelligent design: combination therapy with oncolytic viruses - PubMed (original) (raw)
Review
Intelligent design: combination therapy with oncolytic viruses
Kathryn Ottolino-Perry et al. Mol Ther. 2010 Feb.
Abstract
Metastatic cancer remains an incurable disease in the majority of cases and thus novel treatment strategies such as oncolytic virotherapy are rapidly advancing toward clinical use. In order to be successful, it is likely that some type of combination therapy will be necessary to have a meaningful impact on this disease. Although it may be tempting to simply combine an oncolytic virus with the existing standard radiation or chemotherapeutics, the long-term goal of such treatments must be to have a rational, potentially synergistic combination strategy that can be safely and easily used in the clinical setting. The combination of oncolytic virotherapy with existing radiotherapy and chemotherapy modalities is reviewed along with novel biologic therapies including immunotherapies, in order to help investigators make intelligent decisions during the clinical development of these products.
Figures
**Figure 1
Model of the mechanism of synergy between _γ34.5_-deleted herpes viruses and conventional cancer therapies. _γ34.5_-deleted herpes viruses are favored for oncolytic virotherapy because they show reduced neurotoxicity. Deletion of the γ34.5 gene also results in attenuation of viral replication in tumor cells. Interestingly, γ34.5 shows significant structural homology to a portion of human GADD34, a protein involved in the cells response to DNA damage. γ34.5 is responsible for dephosphorylation of the eukaryotic translation initiation factor eIF-2a, which is required for translation of both host and viral proteins. Radiation or chemotherapy-induced upregulation of GADD34 functionally replaces the γ34.5 protein in infected tumor cells leading to increased viral protein synthesis and production of infectious virus particles.
**Figure 2
Model of tumor killing following treatment with combination oncolytic virotherapy and targeted radionuclide therapy. Initial sites of virus infection often occur in distinct foci surrounding blood vessels (if delivered intravenously) or along the needle track (if delivered intratumorally). Preclinical data indicates that spreading of the virus from these initial sites may be limited. Incomplete transduction of large tumors remains a barrier to effective oncolytic virotherapy. (a) Combination oncolytic virotherapy and targeted radionuclide therapy overcomes the barrier of incomplete transduction due to the radiation cross-fire effect. Uninfected cells falling within the area of the path length (depicted by the dashed lines) will be exposed to radiation resulting in DNA damage and subsequent cell death. (b) Enlarged view of the mechanism of killing at each foci of infection. Infected cells express the virally encoded receptor (for example, vvDD-SSTR2) at the cell surface. The receptors are specifically bound by their cognate radiolabeled peptide analogue from which radiation is emitted. Radiation is emitted in all three-dimensions from the site of origin with a maximum tissue penetration distance defined by the path length (x). Virally induced oncolysis and radiation-induced apoptosis will result in significantly increased tumor cell death relative to either therapy alone.
Similar articles
- Virus combinations and chemotherapy for the treatment of human cancers.
Kumar S, Gao L, Yeagy B, Reid T. Kumar S, et al. Curr Opin Mol Ther. 2008 Aug;10(4):371-9. Curr Opin Mol Ther. 2008. PMID: 18683102 Review. - Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.
Wennier ST, Liu J, McFadden G. Wennier ST, et al. Curr Pharm Biotechnol. 2012 Jul;13(9):1817-33. doi: 10.2174/138920112800958850. Curr Pharm Biotechnol. 2012. PMID: 21740354 Free PMC article. Review. - Modeling the Spatiotemporal Dynamics of Oncolytic Viruses and Radiotherapy as a Treatment for Cancer.
Simbawa E, Al-Johani N, Al-Tuwairqi S. Simbawa E, et al. Comput Math Methods Med. 2020 Apr 12;2020:3642654. doi: 10.1155/2020/3642654. eCollection 2020. Comput Math Methods Med. 2020. PMID: 32411281 Free PMC article. - United virus: the oncolytic tag-team against cancer!
Le Boeuf F, Bell JC. Le Boeuf F, et al. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):205-11. doi: 10.1016/j.cytogfr.2010.02.008. Epub 2010 Mar 12. Cytokine Growth Factor Rev. 2010. PMID: 20227326 Review. - Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones.
Martin NT, Bell JC. Martin NT, et al. Mol Ther. 2018 Jun 6;26(6):1414-1422. doi: 10.1016/j.ymthe.2018.04.001. Epub 2018 Apr 5. Mol Ther. 2018. PMID: 29703699 Free PMC article. Review.
Cited by
- A review of HSV pathogenesis, vaccine development, and advanced applications.
Bai L, Xu J, Zeng L, Zhang L, Zhou F. Bai L, et al. Mol Biomed. 2024 Aug 29;5(1):35. doi: 10.1186/s43556-024-00199-7. Mol Biomed. 2024. PMID: 39207577 Free PMC article. Review. - Treatment of intracranial inflammatory myofibroblastic tumor with PD-L1 inhibitor and novel oncolytic adenovirus Ad-TD-nsIL12: a case report and literature review.
Qian X, Ning W, Dunmall LC, Qu Y, Wang Y, Zhang H. Qian X, et al. Front Immunol. 2024 Jul 24;15:1427554. doi: 10.3389/fimmu.2024.1427554. eCollection 2024. Front Immunol. 2024. PMID: 39114662 Free PMC article. Review. - Oncolytic vaccinia virus immunotherapy antagonizes image-guided radiotherapy in mouse mammary tumor models.
Umer BA, Noyce RS, Kieser Q, Favis NA, Shenouda MM, Rans KJ, Middleton J, Hitt MM, Evans DH. Umer BA, et al. PLoS One. 2024 Mar 18;19(3):e0298437. doi: 10.1371/journal.pone.0298437. eCollection 2024. PLoS One. 2024. PMID: 38498459 Free PMC article. - The Crucial Role of Molecular Biology in Cancer Therapy: A Comprehensive Review.
Gulati P, Singh CV. Gulati P, et al. Cureus. 2024 Jan 14;16(1):e52246. doi: 10.7759/cureus.52246. eCollection 2024 Jan. Cureus. 2024. PMID: 38352075 Free PMC article. Review. - Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors.
Béguin J, Laloy E, Cochin S, Gantzer M, Farine I, Pichon C, Moreau B, Foloppe J, Balloul JM, Machon C, Guitton J, Tierny D, Klonjkowski B, Quéméneur E, Maurey C, Erbs P. Béguin J, et al. Mol Ther Oncolytics. 2023 Jul 20;30:103-116. doi: 10.1016/j.omto.2023.07.005. eCollection 2023 Sep 21. Mol Ther Oncolytics. 2023. PMID: 37635744 Free PMC article.
References
- McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 2000;7:1217–1223. - PubMed
- Dingli D, Peng KW, Harvey ME, Vongpunsawad S, Bergert ER, Kyle RA, et al. Interaction of measles virus vectors with Auger electron emitting radioisotopes. Biochem Biophys Res Commun. 2005;337:22–29. - PubMed
- Idema S, Lamfers ML, van Beusechem VW, Noske DP, Heukelom S, Moeniralm S, et al. AdDelta24 and the p53-expressing variant AdDelta24-p53 achieve potent anti-tumor activity in glioma when combined with radiotherapy. J Gene Med. 2007;9:1046–1056. - PubMed
- Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 2002;62:5736–5742. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources